ARDC Research Link Australia

ORCID Profile
Orcid icon. 0000-0003-2065-3925

Current Organisations
Mayo Clinic , University Hospital of Zurich , Swiss Medical Association (FMH) , GZO Spital Wetzikon , Educational Commission for Foreign Medical Graduates , Praxis am Bahnhof , Centre Hospitalier Universitaire Vaudois , Swiss Medical Assocation FMH , University of Zurich

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.

Publications

Publication

Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey

Publisher: S. Karger AG

Date: 2017

DOI: 10.1159/000475494

Abstract: b i Background: /i /b Long-term data of certolizumab pegol (CZP) in Crohn's disease (CD) from pivotal registry trials are limited. We therefore aimed to evaluate the long-term efficacy of CZP in clinical practice in Switzerland. b i Methods: /i /b In the First Approved Certolizumab Therapeutic Experience in Switzerland-III phase IV multicenter cohort, patients receiving CZP were prospectively included all over Switzerland in (non-) academic hospitals and private practice. b i Results: /i /b We included 104 CD patients (52 male only 22.1% anti-tumor necrosis factor (TNF) naïve, CZP as third anti-TNF agent in 46.2%) with follow-up time between 6 weeks up to 5 years. During treatment with CZP, we observed a significant decrease of the Harvey Bradshaw Index from a median of 7 at baseline (interquartile range 4-11) to 4, 5, 4, 3, 3, and 2 at weeks 6, 26, 52, 78, 104, and 156, respectively. While anti-TNF naïve patients showed a significantly better response at the end of induction, during CZP maintenance therapy response was similar as compared to anti-TNF experienced patients as well as between patients with a short (0-5 years) vs. long duration of disease ( years). b i Conclusions: /i /b CZP is an effective long-term treatment option, including CD patients with long disease duration and prior treatment with 1 or 2 anti-TNF agents.